GeneDx director Dr. Michael Pellini resigns; Section 32 remains supporter after $150M financing

GeneDx Holdings Corp.

Dr. Michael Pellini stepped down from the Board effective February 14, 2023.
Resignation to focus on his role as Managing Partner of Section 32, LLC.
Pellini's departure not due to any disagreement with management or the Board.
GeneDx thanked Section 32 for continued support and participation in January 2023 $150M equity financing.
Company to evaluate whether to fill the vacancy or reduce board size.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Michael Pellini

Director

WGS · GeneDx Holdings Corp.

Effective: 2023-02-14
Filed: February 14, 2023, 6:59 PM ET

On February 14, 2023, Dr. Michael Pellini notified GeneDx Holdings Corp. (“GeneDx”) that he is stepping down from the Board of Directors (the “Board”), effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Michael Pellini departed as Director at GeneDx Holdings Corp..

Action: stepping down
Role: Director

Exact text from the filing

On February 14, 2023, Dr. Michael Pellini notified GeneDx Holdings Corp. (“GeneDx”) that he is stepping down from the Board of Directors (the “Board”), effective immediately

View on SEC.gov

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.